- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: anti PD-L1
Total 162633 results
-
China Meitan General HospitalMarino Biotechnology Co., Ltd.UnknownRecurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant TumorsChina
-
Wuxi People's HospitalRecruitingCancer | PD-L1 Gene MutationChina
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Hoffmann-La RocheRecruitingPD-L1-selected Solid TumorsKorea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus, Georgia
-
Shanghai Zhongshan HospitalRecruiting
-
Consorzio OncotechCompletedMetastatic or Locally Advanced PD-L1 Positive Urothelial CancerItaly
-
Zhongnan HospitalRecruiting
-
Medical University of ViennaUnknownNon Small Cell Lung CancerAustria
-
Baodong QinUnknown
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Inge Marie SvaneCompletedPolycythemia Vera | Essential ThrombocythemiaDenmark
-
Centre Leon BerardNETRIS PharmaRecruitingAdvanced Solid Tumors | Metastatic Solid TumorsFrance
-
Tatarstan Cancer CenterUnknownHereditary Breast CancerRussian Federation
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
ImmunityBio, Inc.Active, not recruitingSolid Tumor | Metastatic Cancer | Locally Advanced Solid TumorUnited States
-
Shanghai Zhongshan HospitalRecruitingCholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4China
-
Lars Møller PedersenCompletedFollicular LymphomaDenmark
-
Hoffmann-La RocheCompletedCarcinoma, Non-Small-Cell Lung | Carcinoma, Small CellUnited Kingdom, Czechia, Germany, Poland, Spain, Switzerland
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
-
Binhui Biopharmaceutical Co., Ltd.Recruiting
-
University Hospital, AngersCompletedCancer | Sleep Apnea Syndromes, ObstructiveFrance
-
Shanghai Zhongshan HospitalRecruitingOesophageal Squamous Cell CarcinomaChina
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Tongji HospitalNational Natural Science Foundation of ChinaRecruitingEsophageal Squamous Cell Carcinoma | Neoadjuvant TherapiesChina
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingNSCLC | Advanced Solid TumorUnited States, China
-
ImmunityBio, Inc.Active, not recruitingMelanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair DeficiencyUnited States
-
Thomas MarronRecruiting
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdSunshine Lake Pharma Co., Ltd.Terminated
-
Sichuan UniversityNot yet recruitingAdvanced Solid TumorChina
-
Peking Union Medical College HospitalRecruitingHepatocellular CarcinomaChina
-
Shanghai Henlius BiotechRecruitingAdvanced Solid TumorChina
-
Herlev and Gentofte HospitalUniversity of CopenhagenCompleted
-
Ascletis Pharmaceuticals Co., Ltd.RecruitingHIV Infections | HIV-1-infection | PD-L1 Gene MutationChina
-
Merck Sharp & Dohme LLCActive, not recruitingCarcinoma, Non-squamous Non-small-cell LungPoland, Korea, Republic of, Ukraine, United States, Argentina, Australia, Austria, Canada, France, Japan, New Zealand, Romania, Russian Federation, Taiwan, Turkey, United Kingdom, Brazil, Colombia, Germany, Spain
-
The Second Hospital of Nanjing Medical UniversityUnknownPrimary Hepatocellular Carcinoma
-
Pyrotech Therapeutics, Inc.RecruitingLocally Advanced or Metastatic Solid TumorsUnited States
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingCervical Cancer | Advanced Solid TumorChina
-
Merck Sharp & Dohme LLCRecruitingSolid Tumors | Hematologic MalignanciesUnited States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more
-
Merck Sharp & Dohme LLCCompletedNon-small Cell Lung CancerChina, Taiwan, Japan, Korea, Republic of, United States, Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Italy, Mexico, Spain, Sweden, United Kingdom
-
Merck Sharp & Dohme LLCActive, not recruitingBreast CancerJapan, Poland, United States, Australia, Belgium, Brazil, Canada, China, Colombia, Costa Rica, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Taiwan, Ukr... and more
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCCompleted
-
Sarah GoldbergMirati Therapeutics Inc.TerminatedLung Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Metastatic Lung Non-Small Cell Carcinoma | PD-L1 Gene Mutation | Pembrolizumab | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Advanced Treatment-Naïve PD-L1 | SitravatinibUnited States
-
Merck Sharp & Dohme LLCActive, not recruitingCarcinoma, Squamous Cell, Non-small-cell LungPoland, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Japan, Mexico, New Zealand, Romania, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
-
Sichuan UniversityRecruitingMalignant Ascites | Malignant Peritoneal Effusion | Serous Cavity MetastatisesChina